Watch LXRX. Know when insiders buy.
One email the day a filing lands. Free.
LXRX
LEXICON PHARMACEUTICALS, INC.
1.46
+0.02 +1.39%
USD · close Nov 3
A free account adds a watchlist, alerts when insiders, Congress or short sellers move on your tickers, and a morning brief. Sign up
Work order
78
PASS · shorts 78
Insiders, 90 days
0
no open-market filings in 90 days
Congress, 90 days
0 / 0
no disclosures naming it
Big money
0 / 15
none of the tracked funds disclose it
Calls on record
0
nobody we score has called it yet
MKT CAP $649.6MP/E —DIV YIELD —FCF YIELD —REV TTM $41.5M −29.0%NET INCOME −$61.1MNET DEBT $58.4M52W 1.14 – 2.64SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q2 2026 · Jun 30 | $692K | −97.6% | 94.4% | −$26.5M | −$31.8M | −1077.1% | -0.07 | −$9.2M | — | — | Aug 6 |
| Q1 2026 · Mar 31 | $21.1M | +1572.1% | 99.5% | −$996K | −$1M | — | 0.00 | −$14.7M | — | — | Aug 6 |
| Q4 2025 · Dec 31derived | $5.5M | −79.3% | 96.3% | −$14.8M | −$15.5M | — | -0.04 | −$17.2M | $0 | −$17.2M | Mar 5 |
| Q3 2025 · Sep 30 | $14.2M | +710.4% | 99.9% | −$12.2M | −$12.8M | — | -0.04 | −$23.8M | $0 | −$23.8M | Nov 6 |
| Q2 2025 · Jun 30 | $28.9M | +1652.6% | 99.9% | $3.7M | $3.3M | — | 0.01 | $17M | — | — | Aug 6 |
| Q1 2025 · Mar 31 | $1.3M | +11.7% | 97.6% | −$25.7M | −$25.3M | — | -0.07 | −$43.8M | — | — | Aug 6 |
| Q4 2024 · Dec 31derived | $26.6M | +3682.6% | 98.7% | −$32.7M | −$33.8M | — | -0.09 | −$21.5M | $474K | −$22M | Mar 5 |
| Q3 2024 · Sep 30 | $1.8M | +980.2% | 95.9% | −$63.7M | −$64.8M | — | -0.18 | −$53.6M | $307K | −$53.9M | Nov 6 |
| Q2 2024 · Jun 30 | $1.6M | — | 89.9% | −$55.4M | −$53.4M | — | -0.17 | −$48.5M | $250K | −$48.8M | Nov 6 |
| Q1 2024 · Mar 31 | $1.1M | — | 97.3% | −$45.3M | −$48.4M | — | -0.20 | −$55.1M | $0 | −$55.1M | Nov 6 |
| Q4 2023 · Dec 31derived | $702K | — | 90.0% | −$46.7M | −$49.8M | — | -0.20 | −$50.5M | $0 | −$50.5M | Mar 5 |
| Q3 2023 · Sep 30 | $162K | — | 95.7% | −$49.6M | −$50.5M | — | -0.21 | −$41.6M | $83K | −$41.7M | Nov 13 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 · to Dec 31 | $49.8M | 99.4% | −$48.9M | −$50.3M | -101.1% | -0.14 | −$67.9M | $0 | −$67.9M | — | — |
| FY2024 · to Dec 31 | $31.1M | 98.0% | −$197.1M | −$200.4M | -644.8% | -0.63 | −$178.8M | $1M | −$179.8M | $1.7M | — |
| FY2023 · to Dec 31 | $1.2M | 92.9% | −$171.8M | −$177.1M | -14710.9% | -0.80 | −$161.9M | $470K | −$162.4M | $824K | — |
| FY2022 · to Dec 31 | $139K | 100.0% | −$100.8M | −$101.9M | -73341.0% | -0.62 | −$88.9M | $1.3M | −$90.2M | $864K | — |
| FY2021 · to Dec 31 | $298K | 100.0% | −$87.1M | −$87.8M | -29449.0% | -0.60 | −$87M | $1.2M | −$88.2M | $2.7M | — |
| FY2020 · to Dec 31 | $24M | 92.0% | −$47.8M | −$58.6M | -244.1% | -0.53 | −$143M | $87K | −$143.1M | $1M | — |
Every number comes from LEXICON PHARMACEUTICALS, INC.'s own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.